Moderna uses mRNA technology to develop vaccines and therapeutics. Its COVID-19 vaccine drove rapid growth; its pipeline targets flu, RSV, and cancer.
Covered calls on MRNA allow shareholders to collect premium income while holding the stock. The most common approach is selling out-of-the-money calls 30-45 days to expiration (DTE) to balance premium income with potential upside. If you own 100 shares of MRNA, you can sell 1 call contract per 100 shares to generate consistent monthly income.
Our screener scans MRNA options every few minutes and ranks setups by annualized return, downside protection, and bid-ask spread quality.
Start Free Trial →